Synthorx (Synthorx) EBIT per Share : $-1.50 (TTM As of Sep. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Synthorx EBIT per Share?

Synthorx's EBIT per Share for the three months ended in Sep. 2019 was $-0.42. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $-1.50.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Synthorx's EBIT per Share or its related term are showing as below:

THOR's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Synthorx's EBIT for the three months ended in Sep. 2019 was $-13.18 Mil.

Synthorx EBIT per Share Historical Data

The historical data trend for Synthorx's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx EBIT per Share Chart

Synthorx Annual Data

Trend

Dec16

Dec17

Dec18

EBIT per Share

-0.36

-0.68

-6.69

Synthorx Quarterly Data
	Dec16	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EBIT per Share	Get a 7-Day Free Trial				-0.22	-0.28	-0.38	-0.43	-0.42

Synthorx EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Synthorx's EBIT per Share for the fiscal year that ended in Dec. 2018 is calculated as

	EBIT per Share		(A: Dec. 2018 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.9	/	3.125
=	-6.69

Synthorx's EBIT per Share for the quarter that ended in Sep. 2019 is calculated as

	EBIT per Share		(Q: Sep. 2019 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-13.177	/	31.788
=	-0.41

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.50

Synthorx (NAS:THOR) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Synthorx EBIT per Share Related Terms

Thank you for viewing the detailed overview of Synthorx's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Synthorx (Synthorx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037

Website

http://www.synthorx.com

Executives

Powell Andrew Kenneth William	director	C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver	director, officer: President and CEO	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022